Extensive Biliary Excretion of the Model Opioid Peptide [D-PEN2,5] Enkephalin in Rats
- 1 January 1997
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 14 (3) , 345-350
- https://doi.org/10.1023/a:1012054222845
Abstract
Purpose. This study was designed to test the hypothesis that the enzymatically stable opioid peptide, [D-pen2,5] enkephalin (DPDPE), is excreted extensively into bile. Methods. Following an i.v. bolus dose of DPDPE (10 mg/kg) to rats, concentrations of DPDPE in serum, bile, liver homogenate and urine were measured by a novel capillary zone electrophoresis method. Data were analyzed to recover the fundamental pharmacokinetic parameters (volumes of distribution; distribution and elimination rate constants governing DPDPE systemic and biliary disposition). Parallel in vitro experiments were performed to evaluate the partitioning of DPDPE between erythrocytes and plasma, as well as to assess the degree of binding of DPDPE to serum proteins. Results. The majority of the administered dose (~80%) was recovered from bile as intact peptide. DPDPE disposition was best described by a two-compartment model with Michaelis-Menten elimination (Km: 37.5 ± 11 μg/ml; Vmax: 1143 ± 368 μg/min/kg) from the central compartment into bile, suggestive of an active hepatic transport system. DPDPE was associated with a distributional space of 486 ± 62 ml/kg. In vitro incubation of DPDPE with whole blood showed that ~65% of the peptide was associated with erythrocytes. The difference between concentrations of DPDPE in erythrocytes and plasma was statistically significant (29.2 ± 4.9 vs. 18.1 ± 3.1 μg/ml, p < 0.05), but not between whole blood and plasma (21.3 ± 2.8 vs. 18.1 ± 3.1 μg/ml, p > 0.05). Concentration-independent binding of DPDPE to serum proteins was evidenced between 10 and 100 (μg/ml, with an unbound fraction of 0.517 ± 0.182. Conclusions. DPDPE undergoes extensive biliary excretion after i.v administration in rats. The apparent nonlinearity in the biliary excretion of DPDPE revealed by the pharmacokinetic modeling strongly suggests the existence of an active transport system(s) in hepatocytes which may mediate the rapid disappearance of DPDPE from the systemic circulation.Keywords
This publication has 19 references indexed in Scilit:
- Development of a capillary zone electrophoresis assay to examine the disposition of [d-pen2,5]enkephalin in ratsJournal of Chromatography B: Biomedical Sciences and Applications, 1996
- SDZ CO 611: a highly potent glycated analog of somatostatin with improved oral activityLife Sciences, 1993
- Factors Influencing the Pharmacokinetics of Cyclosporine in ManTherapeutic Drug Monitoring, 1991
- Hepatocellular transport of cyclosomatostatins: evidence for a carrier system related to the multispecific bile acid transporterBiochimica et Biophysica Acta (BBA) - Biomembranes, 1991
- Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin.Proceedings of the National Academy of Sciences, 1990
- Modified somatostatins as inhibitors of a multispecific transport system for bile acids and phallotoxins in isolated hepatocytesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1985
- Reaction of Opioid Peptides with Neutral Endopeptidase (‘Enkephalinase”)Journal of Neurochemistry, 1984
- Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors.Proceedings of the National Academy of Sciences, 1983
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- Distribution and metabolism of exogenous somatostatin in the ratRegulatory Peptides, 1982